Osimertinib with another drug for advanced solid tumors with EGFR mutation
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination treatment for people with advanced solid tumors that have a specific genetic change called EGFR. The main drug, osimertinib, is already used for lung cancer, and adding another drug may help control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a locally advanced or metastatic solid tumor (cancer that has spread) confirmed by biopsy.
- Your tumor must have an EGFR mutation (a specific genetic change).
- You must be able to receive osimertinib as part of your treatment.
- You must be in generally good health (able to care for yourself) and have a life expectancy of at least 12 weeks.
- You must have at least one tumor lesion that has not been irradiated and can be measured on a CT or MRI scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether adding chemotherapy can help people with EGFR-mutated lung cancer when their cancer-related blood test (liquid biopsy for EGFR DNA) is still positive after 3–4 weeks of starting osimertinib. It may help slow the cancer for longer by treating any remaining disease activity.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
This study tests a new drug (SYS6010) combined with an existing targeted therapy (osimertinib) for people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination works better than standard treatments and to find a safe dose.
This trial tests a personalized treatment plan for advanced lung cancer with an EGFR mutation. It uses a blood test (ctDNA) to guide treatment with osimertinib (a targeted pill) plus chemotherapy. The goal is to see if adjusting therapy based on the blood test results can help you live longer with fewer side effects.
This trial tests whether adding chemotherapy to the standard targeted therapy osimertinib can improve outcomes for people with a specific type of advanced lung cancer that has not responded fully to osimertinib alone. It is for those whose cancer has a particular EGFR mutation and who still have detectable cancer DNA in their blood after starting osimertinib.
Hear when a new NSCLC Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.